Literature DB >> 26776226

MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target.

Giovanna Poce1, Sara Consalvi, Mariangela Biava.   

Abstract

MmpL3 belongs to the Resistance, Nodulation and Division (RND) superfamily whose role in mycobacteria is the formation of the outer membrane. Indeed, it has been shown that MmpL3 is associated with the export of mycolic acids in the form of trehalose monomycolates (TMM) to the periplasmic space or the outer membrane. In the last few years several whole cell-based screenings of compound libraries brought by a number of diverse chemical scaffolds active against M. tuberculosis (Mtb) that surprisingly share MmpL3 as target. The diverse identified pharmacophores owe important differences among each other, in fact while some of them display inhibitory activity against pathogens that are devoid of mycolic acids and are active against non-replicating Mtb bacilli, some others specifically target mycobacteria and do not kill non-replicating bacilli. The scope of this review is to provide the recent advances in MmpL3 inhibitor discovery with a special focus on structure activity relationship (SAR) studies in order to provide information that could help in developing novel membrane-active anti- TB agents. Moreover, this review will provide the most recent insights into the modes of action of the MmpL3 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26776226     DOI: 10.2174/1389557516666160118105319

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  11 in total

1.  A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3.

Authors:  Christian Dupont; Yushu Chen; Zhujun Xu; Françoise Roquet-Banères; Mickaël Blaise; Anne-Kathrin Witt; Faustine Dubar; Christophe Biot; Yann Guérardel; Florian P Maurer; Shu-Sin Chng; Laurent Kremer
Journal:  J Biol Chem       Date:  2019-09-27       Impact factor: 5.157

2.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.

Authors:  Peter C Ray; Margaret Huggett; Penelope A Turner; Malcolm Taylor; Laura A T Cleghorn; Julie Early; Anuradha Kumar; Shilah A Bonnett; Lindsay Flint; Douglas Joerss; James Johnson; Aaron Korkegian; Steven Mullen; Abraham L Moure; Susan H Davis; Dinakaran Murugesan; Michael Mathieson; Nicola Caldwell; Curtis A Engelhart; Dirk Schnappinger; Ola Epemolu; Fabio Zuccotto; Jennifer Riley; Paul Scullion; Laste Stojanovski; Lisa Massoudi; Gregory T Robertson; Anne J Lenaerts; Gail Freiberg; Dale J Kempf; Thierry Masquelin; Philip A Hipskind; Joshua Odingo; Kevin D Read; Simon R Green; Paul G Wyatt; Tanya Parish
Journal:  ACS Omega       Date:  2021-01-13

3.  Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.

Authors:  John T Williams; Elizabeth R Haiderer; Garry B Coulson; Kayla N Conner; Edmund Ellsworth; Chao Chen; Nadine Alvarez-Cabrera; Wei Li; Mary Jackson; Thomas Dick; Robert B Abramovitch
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

4.  HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter.

Authors:  Huiqing Zheng; John T Williams; Garry B Coulson; Elizabeth R Haiderer; Robert B Abramovitch
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

5.  Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for Treating Drug-Resistant Tuberculosis.

Authors:  Hongyi Zhao; Yongxin Gao; Wei Li; Li Sheng; Keli Cui; Bin Wang; Lei Fu; Meng Gao; Ziyun Lin; Xiaowen Zou; Mary Jackson; Haihong Huang; Yu Lu; Dongfeng Zhang
Journal:  J Med Chem       Date:  2022-08-01       Impact factor: 8.039

6.  Screening of Preselected Libraries Targeting Mycobacterium abscessus for Drug Discovery.

Authors:  Adrian Richter; Angelika Strauch; Joseph Chao; Mary Ko; Yossef Av-Gay
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

7.  Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis.

Authors:  Giovanna Poce; Sara Consalvi; Giulia Venditti; Salvatore Alfonso; Nicoletta Desideri; Raquel Fernandez-Menendez; Robert H Bates; Lluis Ballell; David Barros Aguirre; Joaquin Rullas; Alessandro De Logu; Michelle Gardner; Thomas R Ioerger; Eric J Rubin; Mariangela Biava
Journal:  ACS Med Chem Lett       Date:  2019-09-18       Impact factor: 4.345

Review 8.  Targeting MmpL3 for anti-tuberculosis drug development.

Authors:  Jani R Bolla
Journal:  Biochem Soc Trans       Date:  2020-08-28       Impact factor: 5.407

9.  MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections.

Authors:  Wei Li; Amira Yazidi; Amitkumar N Pandya; Pooja Hegde; Weiwei Tong; Vinicius Calado Nogueira de Moura; E Jeffrey North; Jurgen Sygusch; Mary Jackson
Journal:  Front Microbiol       Date:  2018-07-10       Impact factor: 5.640

10.  Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent.

Authors:  Mary A De Groote; Thale C Jarvis; Christina Wong; James Graham; Teresa Hoang; Casey L Young; Wendy Ribble; Joshua Day; Wei Li; Mary Jackson; Mercedes Gonzalez-Juarrero; Xicheng Sun; Urs A Ochsner
Journal:  Front Microbiol       Date:  2018-09-20       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.